Please enable Javascript to use all features and improve your user experience.
ECTES 2023
Programme
People
Search
DE
All people
Marta Kokot-Kierepa
Zurich / CH
Takeda Pharmaceuticals International AG
Sort by Type
Date
Speaker
07/05/2023
12:51
–
12:54
3 Min.
0 Min.
Poster
PS6.03
A phase 3 noninferiority trial to evaluate the efficacy and safety of TAK-330 (4-factor prothrombin complex concentrate [4F-PCC]) versus standard-of-care 4F-PCC for the reversal of factor Xa inhibitor-induced anticoagulation before urgent surgery or an invasive procedure
Emergency surgery
08/05/2023
12:50
–
12:55
3 Min.
2 Min.
Quick shot presentation
QSP11.02
Anticoagulation reversal: The current treatment landscape and unmet needs in the USA
Emergency surgery
Further involvements
07/05/2023
12:51
–
12:54
3 Min.
0 Min.
Poster
PS6.03
A phase 3 noninferiority trial to evaluate the efficacy and safety of TAK-330 (4-factor prothrombin complex concentrate [4F-PCC]) versus standard-of-care 4F-PCC for the reversal of factor Xa inhibitor-induced anticoagulation before urgent surgery or an invasive procedure
Emergency surgery
08/05/2023
12:50
–
12:55
3 Min.
2 Min.
Quick shot presentation
QSP11.02
Anticoagulation reversal: The current treatment landscape and unmet needs in the USA
Emergency surgery
© Conventus Congressmanagement & Marketing GmbH
Imprint
Privacy